Navigation Links
Children's Memorial Research Center, Chicago Becomes a Member of GeneGo's MetaMiner Stem Cell Partnership Program

ST. JOSEPH, Mich., April 14 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Professor Marcelo Bento Soares of Children's Memorial Research Center has joined the MetaMiner Stem Cell Partnership Program. The goal of the program is to develop a series of blueprint pathway maps for adult, embryonic, fetal, fibroblasts, hematopoietic, mesenchymal, multipotent, neoplastic, pluripotent and totipotent stem cells.

"We feel that it is important to support such an initiative as there is a lot of stem cell information in the literature but no one has brought it all together in a set of comprehensive pathway maps," said Professor Marcelo Bento Soares, Director, Cancer Biology and Epigenomics Program. "This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly."

"We had our kick off meeting last month and it went very well; we have a lot of other companies and academic groups that want to join this important project as this will be the first stem cell pathway platform for researchers to advance science. Stem cell research is attracting a lot of attention at the moment," said Julie Bryant, GeneGo's VP of Business Development. "We have a lot of experience in building pathway maps and we plan to have 10 types of stem cell drug centric pathway maps completed in 24 months."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at

About Children's Memorial Research Center

The mission of Children's Memorial Research Center is to generate new knowledge leading to advancements in the prevention, diagnosis, and treatment of diseases that affect the development of children through adolescence as well as adult disorders that derive from them. Our multidisciplinary teams of physicians, scientists, technicians, nurses and trainees are committed to making discoveries that will improve the lives of children and their families.

SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
2. Sigma-Aldrich Welcomes Memorial Sloan-Kettering Cancer Center to the RNAi Partnership Program
3. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
4. Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell
5. Pfizer Animal Health and NTRA Charities Team Up to Benefit the Barbaro Memorial Fund
6. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. Memorial Medical First in Stanislaus County to Provide Convertible Ultrasound From ZONARE
8. New Weapon in BioDefense Research: NanoLogix Kit Speeds Rapid Diagnostics of Anthrax and Bubonic Plague
9. Latest BioTrends Research Reports to Assess the Impact of the Withdrawal of Raptiva (efalizumab) on the Psoriasis Market
10. ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program
11. Researchers develop new way to see single RNA molecules inside living cells
Post Your Comments:
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
(Date:6/23/2016)...  Amgen (NASDAQ: AMGN ) today announced ... life sciences incubator to accelerate the development of new ... at QB3@953 was created to help high-potential life science ... early stage organizations - access to laboratory infrastructure. ... two "Amgen Golden Ticket" awards, providing each winner with ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):